08:58 AM EDT, 03/23/2026 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) and Insitro have expanded their ongoing collaboration to include two new therapeutic targets for the treatment of amyotrophic lateral sclerosis, Insitro said Monday.

Bristol-Myers Squibb ( BMY ) nominated the additional targets, ALS-2 and ALS-3, which were identified through Insitro's Virtual Human platform, Insitro said.

Insitro added that it received a $10 million milestone payment in connection with the selection of the two additional targets.

Shares of Bristol-Myers Squibb ( BMY ) were up 1.3% in Monday's premarket activity.